Director, Investor Relations

About Zenas

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases.

Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self‑administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.

Orelabrutinib is a potentially best‑in‑class, highly selective CNS‑penetrant, oral, small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized inflammation and disease progression in Multiple Sclerosis (MS). Zenas’ earlier stage programs include a preclinical, potentially best‑in‑class, oral, IL‑17AA/AF inhibitor, and a preclinical, potentially best‑in‑class, oral, brain‑penetrant, TYK2 inhibitor.

We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast‑paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence and Innovation –
TRUE Innovation
!

Zenas Bio Pharma is seeking an accomplished Director of Investor Relations to lead development and execution of a comprehensive IR strategy that effectively communicates the company’s scientific platform, clinical progress, regulatory milestones, and financial outlook. Reporting to the Chief Financial Officer, this leader will work closely with executive management, corporate development, and cross‑functional partners to deliver consistent, compliant, and high‑impact communications.

The role is central to shaping external perception, strengthening internal alignment, and supporting a culture of transparency, credibility, and long‑term value creation.

• Develop high‑quality investor‑facing materials including earnings documents, presentations, press releases, fact sheets, and Q&A; translating complex scientific and clinical concepts into clear, accessible content.
• Build and maintain strong relationships with covering analysts, ensuring their research and perspectives remain aligned with company messaging and strategic objectives.
• Collaborate cross‑functionally to craft compelling written materials that support company positioning and effectively communicate program updates during conference calls, investor meetings, and analyst events.
• Partner closely with Finance, Legal, and external advisors to ensure accuracy, consistency, and regulatory compliance across all investor communications.
• Synthesize investor feedback, analyst commentary, and broader market sentiment to deliver actionable insights and recommendations to senior leadership.
• Coordinate logistics and prepare briefing materials for investor and analyst meetings, conference participation, and other external engagements.
• Manage a high‑impact IR events calendar including roadshows, medical and investor conferences, R&D days, and quarterly updates ensuring timely, accurate execution of all deliverables.
• Maintain detailed records of investor interactions, feedback, and follow‑ups to inform leadership and refine the overall IR strategy.
• Establish effective ways of working, resource allocation models, and outcome‑based planning…